

Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease (Influenza, MMR, Pneumonia, Meningitis, Hepatitis, Tap, Hib, Polio, etc) & Companies

<https://marketpublishers.com/r/P812DE8E567EN.html>

Date: July 2018

Pages: 0

Price: US\$ 1,690.00 (Single User License)

ID: P812DE8E567EN

Abstracts

Pediatric Vaccine Market is projected to exceed US\$ 48 Billion by the year 2024. Increasing government and non-government funding for the development of new vaccines, along with raising awareness about the benefits of vaccination, is certainly expected to positively drive the market growth in the coming years. In order to cut the healthcare expenses, governments have been making continuous efforts to reduce the cost of patient immunization through various vaccination programs funded by government or non-government health authorities. For example; several countries have included Children Vaccination Programs, which offers vaccines to children who lack health insurance or one who cannot afford the cost of vaccination.

Growing prevalence of chronic diseases is another major market driver, driving the market of infant (pediatric) vaccines. The immune system is not fully developed in infants, hence they are at a higher risk of contracting severe diseases and so, vaccination plays a significant role in their prevention. According to WHO; effective immunization activities have had a major impact on reducing measles deaths. It is found that measles vaccination prevented an estimated 20.4 million deaths across the globe. Global measles deaths have decreased by 84% from an estimated 550,100 in 2000 to 89,780 in 2016.

Renub Research report titled "Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease [Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella,

and Combination Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Pediatric (Infants) Vaccine Market.

By Disease - Pneumococcal Vaccine is likely to grow at Noteworthy Rate in the Forthcoming Years

The report studies the market of the following vaccine: Influenza, MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, and Combination Vaccine. Pneumococcal and Combination Vaccines together hold the significant market share in pediatric (infants) vaccine market and is expected to continue so during the forecast period.

Nearly 650 Million Vaccines Doses will be administered in Pediatrics (Infants) by the year 2024

As per our analysis; it is estimated that by the year 2024, the doses of vaccines administered will reach nearly 650 Million. The number of vaccine doses is expected to grow considerably during the forecast period due to growing awareness among the parents about the benefits of vaccines and also the developing countries around the world that now have included a number of vaccines to their national immunization programme as per WHO recommendations, which indeed will drive the pediatric vaccine market in recent years.

Regional - Immunization Profile

The report also comprises of the en-detail study of global and regional immunization profile: By Diseases such as Measles, Mumps, Rubella, Diphtheria, Tetanus, Polio and so on and By Regions such as Africa (AFR), Americas (AMR), Eastern Mediterranean (EMR), Europe (EUR), South-East Asia (SEAR), Western Pacific (WPR) and Global.

Company Analysis

GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently in vaccine business globally. These companies have been studied thoroughly in the report.

Global Pediatric (Infants) Vaccine Market has been extensively studied from 3 major points:

1. Pediatrics Vaccines (Disease wise) Market & Forecast
2. Number of Vaccinated Pediatric (Infants) (Disease wise) & Forecast
3. Doses of Vaccines Administered in Pediatric (Infants) (Disease wise) & Forecast

This market research report provides a complete analysis of the Global Pediatric (Infants) Vaccine Market and their projections for the upcoming years, Growth Drivers, Challenges, and Disease wise number of reported cases.

By Disease

Influenza

MMR (Measles, Mumps, and Rubella)

Pneumonia

Meningitis

Hepatitis

Tap (Diphtheria, Tetanus, Pertussis)

Haemophilus influenzae type B

Polio

Rotavirus

Varicella

Combination Vaccine

Key Companies Covered in the Report

GlaxoSmithKline

Merck

Sanofi

Pfizer

Contents

1. RESEARCH FINDINGS

2. PEDIATRIC (INFANT) VACCINES MARKET (2011 – 2024)

3. MARKET & NUMBERS SHARE – PEDIATRIC VACCINES

3.1 Pediatric Vaccine Market Share

3.2 Pediatric Vaccinated Population Share

3.3 Pediatric Doses of Vaccines Administered Share

3.4 Vaccine Companies Market Share

4. PEDIATRIC VACCINATED NUMBERS

5. PEDIATRIC DOSES OF VACCINES ADMINISTERED

6. DISEASE WISE – PEDIATRIC (INFANTS) VACCINES MARKET (2011 – 2024)

6.1 Influenza

6.2 MMR (Measles, Mumps, and Rubella Vaccine)

6.3 Pneumococcal

6.4 Meningococcal

6.5 Hepatitis

6.6 DTaP

6.7 Haemophilus Influenzae Type B (HIB)

6.8 Combos (Combination)

6.9 Polio

6.10 Rotavirus

6.11 Varicella

7. DISEASE WISE – NUMBERS OF VACCINATED PEDIATRIC (INFANTS) (2011 – 2024)

7.1 Influenza

7.2 MMR

7.3 Pneumococcal

7.4 Meningococcal

7.5 Hepatitis

- 7.6 DTaP
- 7.7 Hib (Haemophilus Influenzae Type B)
- 7.8 Combos (Combination Vaccines)
- 7.9 Polio
- 7.10 Rotavirus
- 7.11 Varicella

8. DISEASE WISE – DOSES OF VACCINES ADMINISTERED IN PEDIATRIC (INFANTS) (2011 – 2024)

- 8.1 Influenza
- 8.2 MMR
- 8.3 Pneumococcal
- 8.4 Meningococcal
- 8.5 Hepatitis
- 8.6 DTaP
- 8.7 Hib (Haemophilus Influenzae Type B)
- 8.8 Polio
- 8.9 Rotavirus
- 8.10 Varicella

9. DISEASE WISE - IMMUNIZATION PROFILE

- 9.1 Immunization Coverage (%) in Infants
- 9.2 Global Immunization Profile
- 9.3 Regional Immunization Profile
 - 9.3.1 Measles – Number of Reported Cases
 - 9.3.2 Mumps – Number of Reported Cases
 - 9.3.3 Rubella – Number of Reported Cases
 - 9.3.4 Rubella (CRS) – Number of Reported Cases
 - 9.3.5 Diphtheria – Number of Reported Cases
 - 9.3.6 Tetanus (Neonatal) – Number of Reported Cases
 - 9.3.7 Tetanus (Total) – Number of Reported Cases
 - 9.3.8 Pertussis – Number of Reported Cases
 - 9.3.9 Polio – Number of Reported Cases
 - 9.3.10 Yellow Fever – Number of Reported Cases
 - 9.3.11 Japanese encephalitis – Number of Reported Cases

10. VACCINES KEY PLAYERS SALES (2011 – 2024)

- 10.1 GlaxoSmithKline, plc.'s Vaccines Sales
- 10.2 Merck & Co. Vaccines Sales
- 10.3 Sanofi Pasteur's Vaccines Sales
- 10.4 Pfizer, Inc.'s Vaccines Sales
- 10.5 Global – Other Companies Vaccines Sales

11. VACCINES – PRODUCTS AND PIPELINE

- 11.1 GSK Vaccine Product Pipeline
- 11.2 Merck Vaccine Product Pipeline
- 11.3 Sanofi Vaccine Product Pipeline
- 11.4 Pfizer Vaccine Product Pipeline

12. TOP MERGERS AND ACQUISITIONS IN THE VACCINE INDUSTRY

13. VACCINES AND REGULATOR'S INTERVENTIONS

- 13.1 Making and Meeting Standards of Quality and Safety
- 13.2 Vaccine Funding

14. VACCINE MARKET DRIVERS

- 14.1 Inclusion in National Immunization Schedule
- 14.2 Growing Immunization Coverage for HPV Vaccines
- 14.3 Increase in Prevalence of Infectious Diseases
- 14.4 Global Immunization Vision and Strategy (GIVS)
- 14.5 GAVI Model Fuelling Vaccine Manufacturers
 - 14.5.1 The Partnership Model
 - 14.5.2 The Business Model
- 14.6 Increasing Vaccine Availability in United States
- 14.7 The Vaccine Safety Data link Project
- 14.8 The Vaccine Injury Compensation Program
- 14.9 Transforming of Vaccine Technologies
- 14.10 Global Vaccine Action Plan by WHO (2011 - 2020)
- 14.11 Continuous Focus on Effective Communication Strategies

15. VACCINES MARKET CHALLENGES

- 15.1 Hurdles to Optimal use of Licensed Vaccines
 - 15.1.1 Technical Obstacles
 - 15.1.2 Economic Obstacles
 - 15.1.3 Cultural Obstacles
- 15.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
 - 15.2.1 Legal Obstacles
 - 15.2.2 General Technical Barriers
 - 15.2.3 Economic Barriers
 - 15.2.4 Regulatory Barriers
- 15.3 Shortening the Timeline for Vaccine Development
- 15.4 Refusal/Resistance to Vaccination
 - 15.4.1 Vaccine Adverse Event Reporting System
- 15.5 Vaccine Shortages and Delays
- 15.6 Obstacles in Vaccine Research & Development
- 15.7 Barriers to New Entrants in the Vaccines Market

List Of Figures

LIST OF FIGURES

Figure 2-1: Global – Pediatric (Infant) Vaccines Market (Billion US\$), 2011 – 2017

Figure 2-2: Global – Forecast for Pediatric (Infant) Vaccines Market (Billion US\$), 2018 – 2024

Figure 3-1: Global – Pediatric (Infant) Vaccines Market Share (Percent), 2011 - 2017

Figure 3-2: Global – Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2018 - 2024

Figure 3-3: Global – Vaccinated Infant (Pediatric) Share (Percent), 2011 – 2017

Figure 3-4: Global – Forecast for Vaccinated Infant (Pediatric) Share (Percent), 2018 – 2024

Figure 3-5: Global – Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011 - 2017

Figure 3-6: Global – Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2018 - 2024

Figure 3-7: Global – Key Players Vaccines Market Share (Percent), 2011 - 2017

Figure 3-8: Global – Forecast for Key Players Vaccines Market Share (Percent), 2018 - 2024

Figure 4-1: Global – Number of Vaccinated Infant (Pediatric) (Million), 2011 - 2017

Figure 4-2: Global – Forecast for Number of Vaccinated Infant (Pediatric) (Million), 2018 – 2024

Figure 5-1: Global – Doses of Pediatric (Infant) Vaccines Administered (Million), 2011 - 2017

Figure 5-2: Global – Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2018 - 2024

Figure 6-1: Influenza – Pediatric (Infant) Vaccines Market (Million US\$), 2011 - 2017

Figure 6-2: Influenza – Forecast for Pediatric (Infant) Vaccines Market (Million US\$), 2018 - 2024

Figure 6-3: MMR – Pediatric (Infant) Vaccines Market (Million US\$), 2011 – 2017

Figure 6-4: MMR – Forecast for Pediatric (Infant) Vaccines Market (Million US\$), 2018 - 2024

Figure 6-5: Pneumococcal – Pediatric (Infant) Vaccines Market (Billion US\$), 2011 - 2017

Figure 6-6: Pneumococcal – Forecast for Pediatric (Infant) Vaccines Market (Billion US\$), 2018 - 2024

Figure 6-7: Areas with frequent epidemics of meningococcal meningitis

Figure 6-8: Meningococcal – Pediatric (Infant) Vaccines Market (Million US\$), 2011 -

2017

Figure 6-9: Meningococcal – Forecast for Pediatric (Infant) Vaccines Market (Million US\$), 2018 - 2024

Figure 6-10: Hepatitis – Pediatric (Infant) Vaccines Market (Million US\$), 2011 - 2017

Figure 6-11: Hepatitis – Forecast for Pediatric (Infant) Vaccines Market (Million US\$), 2018 - 2024

Figure 6-12: DTaP – Pediatric (Infant) Vaccines Market (Million US\$), 2011 - 2017

Figure 6-13: DTaP – Forecast for Pediatric (Infant) Vaccines Market (Million US\$), 2018 - 2024

Figure 6-14: Haemophilus Influenzae Type B (HIB) – Vaccines Market (Million US\$), 2011 - 2017

Figure 6-15: Haemophilus Influenzae Type B (HIB) – Forecast for Vaccines Market (Million US\$), 2018 - 2024

Figure 6-16: Combos (Combination) – Vaccines Market (Billion US\$), 2011 - 2017

Figure 6-17: Combos (Combination) – Forecast for Vaccines Market (Billion US\$), 2018 - 2024

Figure 6-18: Polio – Vaccines Market (Million US\$), 2011 - 2017

Figure 6-19: Polio – Forecast for Vaccines Market (Million US\$), 2018 - 2024

Figure 6-20: Rotavirus Deaths Under Five Years of Age per 100 000 Population 5 Years of Age, 2013

Figure 6-21: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013

Figure 6-22: Rotavirus – Vaccines Market (Million US\$), 2011 - 2017

Figure 6-23: Rotavirus – Forecast for Vaccines Market (Million US\$), 2018 - 2024

Figure 6-24: Varicella – Pediatric (Infant) Vaccines Market (Million US\$), 2011 - 2017

Figure 6-25: Varicella – Forecast for Pediatric (Infant) Vaccines Market (Million US\$), 2018 - 2024

Figure 7-1: Influenza – Number of Vaccinated Infants (Million), 2011 - 2017

Figure 7-2: Influenza – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024

Figure 7-3: MMR – Number of Vaccinated Infants (Pediatric) (Million), 2011 - 2017

Figure 7-4: MMR – Forecast for Number of Vaccinated Infants (Pediatric) (Million), 2018 - 2024

Figure 7-5: Pneumococcal – Number of Vaccinated Infants (Million), 2011 - 2017

Figure 7-6: Pneumococcal – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024

Figure 7-7: Meningococcal – Number of Vaccinated Infants (Million), 2011 - 2017

Figure 7-8: Meningococcal – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024

Figure 7-9: Hepatitis – Number of Vaccinated Infants (Million), 2011 - 2017

Figure 7-10: Hepatitis – Forecast for Number of Vaccinated Infants (Million), 2018 -

2024

Figure 7-11: DTaP – Number of Vaccinated Infants (Million), 2011 - 2017

Figure 7-12: DTaP – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024

Figure 7-13: Hib (Haemophilus Influenzae Type B) – Number of Vaccinated Infants (Million), 2011 - 2017

Figure 7-14: Hib (Haemophilus Influenzae Type B) – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024

Figure 7-15: Combos (Combination Vaccines) – Number of Vaccinated Infants (Million), 2011 - 2017

Figure 7-16: Combos (Combination Vaccines) – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024

Figure 7-17: Polio – Number of Infants Immunized (Million), 2011 - 2017

Figure 7-18: Polio – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024

Figure 7-19: Rotavirus – Number of Infants Immunized (Million), 2011 - 2017

Figure 7-20: Rotavirus – Forecast for Number of Infants Immunized (Million), 2018 - 2024

Figure 7-21: Varicella – Number of Vaccinated Infants (Million), 2011 - 2017

Figure 7-22: Varicella – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024

Figure 8-1: Influenza – Doses of Infant Vaccines Administered (Million), 2011 - 2017

Figure 8-2: Influenza – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024

Figure 8-3: MMR – Doses of Infant Vaccines Administered (Million), 2011 - 2017

Figure 8-4: MMR – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024

Figure 8-5: Pneumococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2017

Figure 8-6: Pneumococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024

Figure 8-7: Meningococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2017

Figure 8-8: Meningococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024

Figure 8-9: Hepatitis – Doses of Infant Vaccines Administered (Million), 2011 - 2017

Figure 8-10: Hepatitis – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024

Figure 8-11: DTaP – Doses of Infant Vaccines Administered (Million), 2011 - 2017

Figure 8-12: DTaP – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024

Figure 8-13: Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered (Million), 2011 - 2017

Figure 8-14: Hib (Haemophilus Influenzae Type B) – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024

Figure 8-15: Polio – Doses of Infant Vaccines Administered (Million), 2011 - 2017

Figure 8-16: Polio – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024

Figure 8-17: Rotavirus – Doses of Infant Vaccines Administered (Million), 2011 - 2017

Figure 8-18: Rotavirus – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024

Figure 8-19: Varicella – Doses of Infant Vaccines Administered (Million), 2011 - 2017

Figure 8-20: Varicella – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024

Figure 10-1: Global - GlaxoSmithKline, plc.'s Vaccines Sales (Billion US\$), 2011 - 2017

Figure 10-2: Global – Forecast for GlaxoSmithKline, plc.'s Vaccines Sales (Billion US\$), 2018 - 2024

Figure 10-3: Global - Merck & Co. Vaccines Sales (Billion US\$), 2011 - 2017

Figure 10-4: Global – Forecast for Merck & Co. Vaccines Sales (Billion US\$), 2018 - 2024

Figure 10-5: Global - Sanofi Pasteur's Vaccines Sales (Billion US\$), 2011 - 2017

Figure 10-6: Global – Forecast for Sanofi Pasteur's Vaccines Sales (Billion US\$), 2018 - 2024

Figure 10-7: Global - Pfizer, Inc.'s Vaccines Sales (Billion US\$), 2011 - 2017

Figure 10-8: Global – Forecast for Pfizer, Inc.'s Vaccines Sales (Billion US\$), 2018 - 2024

Figure 10-9: Global – Other Companies Vaccines Sales (Billion US\$), 2011 - 2017

Figure 10-10: Global – Forecast for Other Companies Vaccines Sales (Billion US\$), 2018 - 2024

Figure 11-1: GSK Vaccine Product Pipeline

Figure 14-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule

Figure 14-2: Number of Cases of Diphtheria, Pertussis, Tetanus & Measles by Major Region Worldwide, 2013

Figure 14-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers

Figure 14-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers

Figure 14-5: US Retail Clinics Expected to Surge by 2017

List Of Tables

LIST OF TABLES

- Table 9-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
- Table 9-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2016
- Table 9-3: Vaccines – Number of Reported Cases, 2011 – 2017
- Table 9-4: Measles – Number of Reported Cases, 2001 – 2016
- Table 9-5: Mumps – Number of Reported Cases, 2001 - 2016
- Table 9-6: Rubella – Number of Reported Cases, 2001 - 2016
- Table 9-7: Rubella (CRS) – Number of Reported Cases, 2001 - 2016
- Table 9-8: Diphtheria – Number of Reported Cases, 2001 - 2016
- Table 9-9: Tetanus (Neonatal) – Number of Reported Cases, 2001 – 2016
- Table 9-10: Tetanus (Total) – Number of Reported Cases, 2001 - 2016
- Table 9-11: Pertussis – Number of Reported Cases, 2001 - 2016
- Table 9-12: Polio – Number of Reported Cases, 2001 - 2016
- Table 9-13: Yellow Fever – Number of Reported Cases, 2001 - 2016
- Table 9-14: Japanese Encephalitis – Number of Reported Cases Reported, 2006 - 2016
- Table 11-1: Merck Vaccine Product Pipeline
- Table 11-2: Sanofi Vaccine Product Pipeline
- Table 11-3: Pfizer Vaccine Product Pipeline
- Table 12-1: Vaccine Mergers & Acquisitions
- Table 14-1: United States Immunization Schedule
- Table 14-2: Afghanistan Immunization Schedule
- Table 14-3: Norway Immunization Schedule
- Table 14-4: India Immunization Schedule
- Table 14-5: Vietnam Immunization Schedule
- Table 14-6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
- Table 14-7: Goal-Level Indicators, 2015 & 2020
- Table 14-8: Improvement Strategies or Requirements – the Joint Commission and the Project's Collaborating Organizations

I would like to order

Product name: Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease (Influenza, MMR, Pneumonia, Meningitis, Hepatitis, Tap, Hib, Polio, etc) & Companies

Product link: <https://marketpublishers.com/r/P812DE8E567EN.html>

Price: US\$ 1,690.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P812DE8E567EN.html>